In a ribbon-cutting ceremony held on October 30, 2009, Sartorius (Goettingen, Germany) inaugurated its new plant at the Sartorius Group's location in Bangalore, India.
In a ribbon-cutting ceremony held on October 30, 2009, Sartorius (Goettingen, Germany) inaugurated its new plant at the Sartorius Group's location in Bangalore, India. The new facility is designed to supply the Indian marketplace and additional Asian markets.
CEO Joachim Kreuzburg, Arnold Picot, supervisory board chairman, and Amit Chatterjee, managing director of Sartorius India, officially started up operations at the large building complex. At its new site, Sartorius has combined its five decentralized individual locations in Bangalore into a single new plant on premises, thus creating new capacity for the company's Indian business in both Group divisions.
The company's expanded capacity in India enables it to create and develop new process technologies and to custom-tailor these to meet customers' individual process requirements, according to the company press release.
Among other products, Sartorius in Bangalore, India, develops and manufactures bioreactors and additional equipment for pharmaceutical customers, laboratory equipment, as well scales and other weighing equipment for industrial applications.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.